PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15134839

Development of orbitofrontal function: current themes and future directions.

Keith Happaney·Philip David Zelazo·Donald T Stuss
View original source ↗Export metadata ↓

Abstract

In recent years, an exciting thrust in the developmental research literature has been the focus on "executive" functions (EF). However, the emphasis has been on the more purely cognitive aspects of EF operative in abstract reasoning and problem solving-aspects associated mainly with dorsolateral frontal regions. Although the literature on adult neuropsychology has seen an emerging and growing interest in the study of processes more related to orbitofrontal cortex (OFC), including emotion and personality, research on the development of EF has lagged behind. This special issue of Brain and Cognition is intended to redress this imbalance by bringing together researchers who are studying the nature and development of orbitofrontal function from a wide variety of perspectives.

Explore related subjects

AffectCognitionCognitive ScienceDecision MakingForecastingFrontal LobeHumansMental ProcessesNerve NetNeuropsychologyPrefrontal CortexProblem SolvingJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Keith Happaney, Philip David Zelazo, Donald T Stuss. 2004. Development of orbitofrontal function: current themes and future directions.. https://doi.org/10.1016/j.bandc.2004.01.001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Emotional disclosure for whom? A study of vagal tone in bereavement.

Recent investigations have shown little evidence that written disclosure benefits bereaved individuals over a control condition. The present study hypothesized that the effectiveness of written disclosure for bereavement may be moderated by vagal tone, as indexed by respiratory sinus arrhythmia (RSA). Vagal tone has been identified as an important individual difference in depression. The present study investigated 35 bereaved participants in a longitudinal design, with participants writing each week for 3 weeks, and then participating in follow-up sessions 1 week and 1 month later. As with previous studies, bereaved participants showed improvement, although no differential improvement was seen in the emotional Disclosure group compared to a Control writing group. As hypothesized, however, those participants with the highest RSA benefited most from the written disclosure, while RSA level did not predict outcome in the control condition. Future research should investigate whether vagal tone moderates the impact of written disclosure for non-bereaved individuals.

Affect↗
PubMed2004

Effects of D-cycloserine on negative symptoms in schizophrenia.

INTRODUCTION: The negative and cognitive symptoms of schizophrenia are poorly responsive to neuroleptic treatment. Glutamatergic dysfunction may mediate some of these symptoms. Low dose D-cycloserine (DCS) is a partial agonist at the glycine site of the NMDA-associated receptor complex, noncompetitively enhancing NMDA neurotransmission. Prior studies suggest a beneficial effect of DCS on negative symptoms and cognition. This treatment trial was initiated to confirm and extend these findings. METHODS: Twenty-two male schizophrenic subjects displaying prominent negative symptoms who were stabilized on typical neuroleptics completed the study. A randomized double-blind parallel group design was used to compare the effects of 50 mg p.o. QD of DCS to placebo over 4 weeks. The two subject groups did not differ significantly in age, age of onset of illness or time on current neuroleptic treatment. Symptoms were rated by means of the SANS, BPRS and Abrams and Taylor rating scale. Cognition was assessed with the Sternberg Memory Test and the Continuous Performance Test. RESULTS: Both medication groups improved over the 4 weeks of treatment. However, there were no significant differences between the DCS and placebo group on any symptom rating. DCS effects on cognition did not differ from placebo. DISCUSSION: This study did not detect improvement in negative symptoms or cognitive performance with DCS treatment that has been found in some prior studies. This negative finding may be attributed to small sample size, relatively short duration of treatment and the overall modest effect of DCS. Future studies of DCS should be adequately powered to detect a small to medium effect size and should provide for a longer treatment phase than was used in this study in order to avoid a type II error.

Affect↗
PubMed2004

Well-being and affective style: neural substrates and biobehavioural correlates.

One of the most salient features of emotion is the pronounced variability among individuals in their reactions to emotional incentives and in their dispositional mood. Collectively, these individual differences have been described as affective style. Recent research has begun to dissect the constituents of affective style. The search for these components is guided by the neural systems that instantiate emotion and emotion regulation. In this article, this body of research and theory is applied specifically to positive affect and well-being. The central substrates and peripheral biological correlates of well-being are described. A resilient affective style is associated with high levels of left prefrontal activation, effective modulation of activation in the amygdala and fast recovery in response to negative and stressful events. In peripheral biology, these central patterns are associated with lower levels of basal cortisol and with higher levels of antibody titres to influenza vaccine. The article concludes with a consideration of whether these patterns of central and peripheral biology can be modified by training and shifted toward a more salubrious direction.

Affect↗